Korea Biomedical Review

[Reporter's Notebook] After years of billion-dollar licensing deals, Korea’s biotech boom faces its reckoning.

For years, Korea’s biotech sector has announced licensing agreements valued in the trillions of won, figures that can translate into hundreds of millions or even billions of dollars. The totals were o ...
Korea Biomedical Review

Bill seeks to shield doctors’ apologies from use as court evidence

Doctors’ expressions of regret after medical incidents may soon be legally protected from being used as court evidence under a newly introduced bill.The bill also proposes establishing an independent ...
Korea Biomedical Review

ER doctors slam government transfer reform as ‘disaster,’ call for immediate halt

Emergency medicine specialists have strongly opposed the government’s “pilot project for innovation in the patient transfer ...
Korea Biomedical Review

Korean Organization for Rare Diseases elects MS advocate Yoo Ji-hyeon as new president

Yoo Ji-hyeon, head of the Korean Multiple Sclerosis Society, has been elected president of the Korean Organization for Rare Diseases (KORD).KORD announced Tuesday that Yoo was elected during its regul ...
Korea Biomedical Review

AKOM flags rise in AI-generated ‘fake oriental doctors’ used in product ads

The Association of Korean Medicine (AKOM), a group of Korean medicine practitioners, has issued a warning following a series of cases in which AI-generated “fake oriental medicine doctors” were used t ...
Korea Biomedical Review

Curocell’s Rimqarto achieves 1st confirmed 5-year cure in high-risk lymphoma

A high-risk blood cancer patient has been declared cured after receiving Curocell’s Rimqarto (anitocabtagene autoleucel), a ...
Korea Biomedical Review

MFDS bets on early intervention to cut rare disease drug delays

The greatest challenge in developing treatments for rare diseases is not only scientific complexity. With small patient populations and limited clinical data, delays in development can directly mean l ...
Korea Biomedical Review

Samjin Pharm rolls out brivaracetam epilepsy drug Bricetam

Samjin Pharmaceutical said Tuesday that it has launched Bricetam Tablets (brivaracetam), a third-generation epilepsy treatment.According to Samjin Pharmaceutical, Bricetam Tab maintains the mechanism ...
Korea Biomedical Review

EuBiologics' shingles vaccine EuHZV matches active control in phase 1 interim data

EuBiologics, a Korean vaccine developer, said Wednesday that an interim analysis of its phase 1 clinical trial for its candidate shingles vaccine, EuHZV, confirmed safety and immunogenicity comparable ...
Korea Biomedical Review

Daewoong licenses microneedle technology to push into obesity therapeutics

Daewoong Pharmaceutical said on Wednesday that it signed a global exclusive license agreement with its affiliate Daewoong ...
Korea Biomedical Review

GC Biopharma’s anthrax vaccine Barythrax wins grand prize at Korea New Drug Development Awards

GC Biopharma said Wednesday that Barythrax Injection, the world's first recombinant anthrax vaccine jointly developed with ...
Korea Biomedical Review

Korea to add colonoscopy to national screening from 2028, expand lung cancer screening

Korea will add colonoscopy to its national cancer screening program in 2028 and widen lung cancer screening under a new ...